Vimta Labs Ltd P/E Ratio

The P/E Ratio of Vimta Labs Ltd is 29.6 as of 26 Jul 9.00 AM .a1#The P/E Ratio of Vimta Labs Ltd changed from 19.1 on March 2020 to 24 on March 2024 . This represents a CAGR of 4.67% over 5 years. a1#The Latest Trading Price of Vimta Labs Ltd is ₹ 548.1 as of 25 Jul 15:30 .a1#The PE Ratio of Healthcare Industry has changed from 45.2 to 44.2 in 5 years. This represents a CAGR of -0.45%a1# The PE Ratio of Automobile industry is 18.9. The PE Ratio of Finance industry is 23.0. The PE Ratio of Healthcare industry is 57.6. The PE Ratio of IT - Software industry is 29.1. The PE Ratio of Retail industry is 143.1. The PE Ratio of Textiles industry is 24.3. In 2024a1#The Market Cap of Vimta Labs Ltd changed from ₹ 130.94 crore on March 2020 to ₹ 985.7 crore on March 2024 . This represents a CAGR of 49.74% over 5 years. a1#The Revenue of Vimta Labs Ltd changed from ₹ 80.02 crore to ₹ 82.45 crore over 9 quarters. This represents a CAGR of 1.34% a1#The EBITDA of Vimta Labs Ltd changed from ₹ 24.8 crore to ₹ 25.21 crore over 9 quarters. This represents a CAGR of 0.73% a1#The Net Pr of Vimta Labs Ltd changed from ₹ 12.04 crore to ₹ 12.28 crore over 9 quarters. This represents a CAGR of 0.88% a1#The Dividend Payout of Vimta Labs Ltd changed from 17.46 % on March 2019 to 11.41 % on March 2024 . This represents a CAGR of -6.84% over 6 years. a1#

Vimta Labs Ltd., established in 1984, is India's most comprehensive contract research and testing organization, providing wide range of services to pharmaceutical, biopharmaceutical, food, consumer goods, electronic, electrical, agrochemical, healthcare, medical device and many other industries. Broadly, these services include: Drug discovery, development and drug life cycle management support services in the areas of preclinical research (GLP and non-GLP), clinical research, central lab, and cGMP as well as non-GMP analytical services for pharmaceutical and biopharmaceutical companies; Preclinical research and testing services for medical device companies; Contract research and testing for Agro-science companies; Food testing and analytical development services to support manufacturers, processors, farmers, retailers, traders, exporters, regulators; Clinical diagnostics services to patients, clinicians, hospitals and Environmental regulatory services such as impact assessments and post project monitoring, to industries such as infrastructure, power, cement, oil & gas, mining etc. The Company was awarded ISO 9002 Certification under ISO/IEC Guide-25 as Certified Competent Laboratory and Quality Endorsed Company by Standards Australia Quality Assurance Services Pty. Ltd in 1994. In 1997, the Company entered into a Joint Venture with Russian Centre for Testing and Certification, ROSTEST Moscow with an investment of 24% of the total Paidup Captial. The main essence of this Joint Venture was to diversify the activities in to preshipment inspection services for all Indian exports to Russia. During 2002, the company begun to offer Clinical Diagnostics Services. Clinical Specialty Diagnostics has been an internal requirement to screen the clinical trial subjects. Facilities were created in the year 2000 to speed up the clinical trials. The Company is now expanding its operations by five times of its existing capacities at S P Biotech Park, Genome Valley, Turkapally Village, Shamirpet Mandal, Ranga Reddy Dist. The project is expected to commence from September 2005. During the year 2006-07, the Analytical and Clinical Reference Lab facilities was shifted from the existing Cherlapally Facility to the newly established Life Sciences Facility in S.P.Biotech Park, Genome Valley, Hyderabad which started commercial operations from September, 2006. During the year 2020 Company acquired 100% Equity Shares of Emtac Laboratories Private Limited, on 04th March 2020, making Emtac a wholly owned subsidiary of the Company.